Moderna's new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company's original Spikevax ... Moderna's first bivalent shot mRNA-1273. ...

The new version – dubbed Spikevax Bivalent Original/Omicron – has been given conditional authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) based on phase 2/3 ...

4 and BA.5 sub-variants. So far, the only bivalent vaccines developed and approved for use in humans are the adapted versions of Moderna Spikevax and Pfizer-BioNTech Comirnaty. People over 50 ...

Moderna Inc. said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher ...

According to the lawsuit, the development of Moderna’s COVID-19 vaccine, Spikevax, depended on key technological advancements made at Northwestern. Also Read: Alnylam’s Concedes Its Patent ...

On Thursday, the federal health regulator announced it has given the green light to Moderna's Omicron-targeting bivalent COVID-19 vaccine, for those ages 18 years and older. The "Spikevax Bivalent ...

In a press release issued in Denmark by the Danish Medicines Agency, media have been informed that a side effect of taking Moderna's COVID vaccine, also known as Spikevax, may result in chronic hives.

adding that the bivalent Moderna Spikevax booster is safe and effective with the same mild adverse reactions that resolved quickly, Xinhua news agency reported. Clinical trial results showed that ...

Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...

The lawsuit said, opens new tab Moderna uses Northwestern-developed lipid nanoparticle (LNP) technology without a license in Spikevax shots to transport fragile messenger RNA into the human body.

which accused the company of misusing the school's innovations to develop its blockbuster COVID-19 vaccine Spikevax. British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in ...